Market data not licensed for redistribution.
Medipost
078160 ยท KOSDAQ ยท Manufacture of Basic Pharmaceutical Products
Close
Source: Financial Services Commission stock price data (data.go.kr), updated once a day.
Daily price, 1 year
Key statistics
Market cap (KRW bn)โ
PERโ
PBRโ
ROE %-8.7
Debt ratio % (liabilities / equity)104
Revenue TTM (KRW bn)74.8
Op. profit TTM (KRW bn)-76.5
Dividend yield %โ
Basis: market cap at โฆ; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (consolidated). PER is not shown when TTM net income is negative.
Upcoming risk events
Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.
| 2026-12-30 | Convertible bonds (CB): conversion / exercise period starts โ 4.10% of shares ยท price โฉ17,981 ยท refix floor โฉ12,587 (70.0%) ยท size โฉ30.0bn | Medium |
| 2026-12-30 | Convertible bonds (CB): conversion / exercise period starts โ 3.40% of shares ยท price โฉ17,981 ยท refix floor โฉ12,587 (70.0%) ยท size โฉ25.0bn | Medium |
| 2027-01-06 | Convertible bonds (CB): conversion / exercise period starts โ 12.40% of shares ยท price โฉ17,981 ยท refix floor โฉ12,587 (70.0%) ยท size โฉ100.0bn | High |
| 2027-01-13 | Convertible bonds (CB): conversion / exercise period starts โ 6.60% of shares ยท price โฉ17,981 ยท refix floor โฉ12,587 (70.0%) ยท size โฉ50.0bn | Medium |
Annual results (KRW bn)
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | 54.9 | 64.2 | 68.6 | 70.7 | 73.7 |
| Operating profit | -5.2 | -17.4 | -25.1 | -48.5 | -68.0 |
| Net income | -1.0 | 2.1 | 5.0 | -63.4 | -86.0 |
Quarterly results (KRW bn, 3 months)
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 | |
|---|---|---|---|---|---|---|
| Revenue | 19.2 | 17.8 | 18.7 | 17.9 | 19.5 | 18.8 |
| Operating profit | -13.7 | -19.0 | -14.1 | -21.3 | -16.9 | -24.3 |
| Net income | -16.5 | -24.3 | -17.2 | -28.0 | -10.7 | 32.2 |
Largest shareholder
As of the 2025 annual report: ์ค์นด์ด๋ฉ๋ ์ ํํ์ฌ and related parties hold 47.21% of common shares.
Recent disclosures
| Date | Filing | Summary | |
|---|---|---|---|
| 2026-10-29 | Acquisition of shares in another company ํ๋ฒ์ธ์ฃผ์๋ฐ์ถ์์ฆ๊ถ์ทจ๋๊ฒฐ์ | DART original | |
| 2026-10-29 | Governance / misc. (routine) ๋ํ์ด์ฌ๋ณ๊ฒฝ | DART original | |
| 2026-10-29 | Shareholder meeting ์์์ฃผ์ฃผ์ดํ๊ฒฐ๊ณผ | DART original | |
| 2026-10-29 | Governance / misc. (routine) ์ฃผ์๋งค์์ ํ๊ถ๋ถ์ฌ์๊ดํ์ ๊ณ | DART original | |
| 2026-10-29 | Governance / misc. (routine) ๋ ๋ฆฝ์ด์ฌ์์ ์ใํด์๋๋์ค๋ํด์์๊ดํ์ ๊ณ | DART original | |
| 2026-10-14 | Shareholder meeting ์๊ฒฐ๊ถ๋๋ฆฌํ์ฌ๊ถ์ ์ฐธ๊ณ ์๋ฅ | DART original | |
| 2026-10-14 | Shareholder meeting ์ฃผ์ฃผ์ดํ์์ง๊ณต๊ณ | DART original | |
| 2026-09-15 | Shareholder meeting ์ฃผ์ฃผ๋ช ๋ถํ์๊ธฐ๊ฐ๋๋๊ธฐ์ค์ผ์ค์ | DART original | |
| 2026-09-15 | Shareholder meeting ์ฃผ์ฃผ์ดํ์์ง๊ฒฐ์ | DART original | |
| 2026-08-14 | Periodic report (annual/half/quarterly) ๋ฐ๊ธฐ๋ณด๊ณ ์ (2026.06) | DART original | |
| 2026-07-13 | CB conversion / price adjustment ์ ํ๊ฐ์ก์์กฐ์ | DART original | |
| 2026-07-06 | CB conversion / price adjustment ์ ํ๊ฐ์ก์์กฐ์ | DART original |
Past material filings and price reaction (market-adjusted)
| Date | Filing type | On the news (vs. market) | Next day (vs. market) | 20 days (vs. market) |
|---|---|---|---|---|
| 2026-06-04 | Acquisition of shares in another company | -0.4% | -2.5% | -6.6% |
| 2026-02-23 | Revenue/profit change >=30% (15% large caps) | -1.4% | -1.1% | -1.3% |
| 2026-01-16 | Acquisition of shares in another company | +0.8% | -0.4% | +30.3% |
| 2025-12-31 | Other material event (investment-relevant) | -0.5% | -11.3% | +12.8% |
| 2025-12-17 | Convertible bond issuance | -2.3% | +9.6% | -24.0% |
| 2025-12-16 | Convertible bond issuance | +9.9% | -0.8% | -25.9% |
| 2025-09-26 | Acquisition of shares in another company | -0.5% | -3.8% | +13.5% |
| 2025-03-12 | Rights offering (paid-in capital increase) | -1.5% | -3.1% | +2.4% |
| 2025-02-19 | Revenue/profit change >=30% (15% large caps) | +1.4% | +4.3% | +12.7% |
| 2024-12-24 | Clinical trial / regulatory approval | -8.9% | -4.9% | +2.1% |
For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer โ Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
ยฉ Crypvu ยท Crypto market view
Market data not licensed for redistribution.
ยฉ Crypvu ยท Crypto market view